Oblimersen sodium
Modify Date: 2025-08-25 11:37:49
Oblimersen sodium structure
|
Common Name | Oblimersen sodium | ||
|---|---|---|---|---|
| CAS Number | 190977-41-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C172H204N62Na17O91P17S17 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Oblimersen sodiumOblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research[1][2][3]. |
| Name | Oblimersen sodium |
|---|---|
| Synonym | More Synonyms |
| Description | Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) decreases BCL-2 protein expression in vitro[1]. Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) increases radiation-induced apoptosis[1]. Cell Cycle Analysis[1] Cell Line: Human small-cell lung cancer cell lines H69 Concentration: 500 nM Incubation Time: 72 hours Result: Decreased BCL-2 protein levels. Cell Cycle Analysis[1] Cell Line: Human small-cell lung cancer cell lines H69 Concentration: 500 nM Incubation Time: 72 hours Result: Arrested cell cycle at sub G1 phase. |
| In Vivo | Oblimersen (10 mg/kg; i.p.; daily, for 6 days; nude mice bearing H69 xenografts) decreases tumoural vascularisation in vivo[1]. Oblimersen (5-10 mg/kg; i.p.; daily (Monday to Friday), for 3 weeks) has antitumor efficacy in the subcutaneous tumor model[2]. Animal Model: Male severe combined immunodeficient (SCID)-RAG2 mice[2] Dosage: 5 and 10 mg/kg Administration: Intraperitoneal injection; daily (Monday to Friday), for 3 weeks Result: Inhibited tumor growth in a dose-dependent manner. |
| References |
| Molecular Formula | C172H204N62Na17O91P17S17 |
|---|
| GENASENSE |
| Oblimersen sodium |